CD274 and hepatocellular carcinoma: In 2020, the combination of an anti-VEGF therapy (bevacizumab) plus the PD-L1 inhibitor atezolizumab was established as a new standard of care for patients with advanced HCC based on the demonstration of superior overall survival versus the prior standard of care sorafenib, and multiple additional combinations of anti-VEGF and immune checkpoint therapeutic combinations are in late stages of development.